Twists and Turns in The Fibrinolytic Therapy of Infero-Posterior ST Elevation Myocardial Infarction and Right Ventricular Infarction Patient with Cardiogenic Shock: A Case Report
DOI:
https://doi.org/10.20956/nmsj.v10i2.45901Abstract
Introduction: Fibrinolytic therapy is preferred for ST-segment elevation myocardial infarction (STEMI) when the timeframe for percutaneous coronary intervention (PCI) cannot be achieved. Although effective, fibrinolytics are also associated with several adverse effects in addition to the complications of STEMI itself. Case: A 45-year-old active smoker man presented with chest pain, dyspnea, and diaphoresis for the past hour. Electrocardiography revealed infero-posterior STEMI with right ventricular infarction. Echocardiography demonstrated akinetic inferior, infero-septal, and posterior walls with an estimated right atrial pressure of 15 mmHg. Management: Therapy consisted of aspirin, clopidogrel, furosemide, and streptokinase infusion. Within five minutes of initiating streptokinase, the patient developed sudden hypotension that required norepinephrine, dobutamine, and dopamine. At approximately halfway of the streptokinase infusion, he developed accelerated idioventricular rhythm which progressed to pulseless ventricular tachycardia lasting for one minute. Before defibrillation was performed, his rhythm reverted to sinus, after which a bolus of amiodarone was administered. Given his instability, streptokinase was discontinued after approximately 70 percent of the total dose had been delivered. Outcome: The patient was transferred to the intensive care unit with stable hemodynamic, resolved chest pain, and more than 50 percent ST-segment resolution on ECG. Heparin, atorvastatin, maintenance amiodarone, and furosemide were added to his regimen. He continued to improve clinically and was discharged without complication. Conclusion: This case shows that fibrinolysis remains essential when PCI is unavailable, but streptokinase can cause hemodynamic and arrhythmic complications, highlighting the need for close monitoring and rapid intervention in resource-limited settings.
References
1. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720–826.
2. Rahman A, Hasan KAMM, Hanufa MU. Study of Adverse Events of Streptokinase Therapy in Patients with Acute ST Elevation Myocardial Infarction. World J Cardiovasc Dis. 2020 Jul 13;10(7):500–8.
3. Thakkar D, Ramalingam R, Palakshachar A, Patil S, Subramanyam K, Moorthy N, et al. A study on clinical profile and in-hospital outcome of elderly patients receiving thrombolytic therapy for ST elevation myocardial infarction. J Indian Coll Cardiol. 2022 Jan 1;12(1):14–14.
4. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. The Lancet. 1996 Sep 21;348(9030):771–5.
5. Diwan D, Usmani Z, Sharma M, Nelson JW, Thakur VK, Christie G, et al. Thrombolytic Enzymes of Microbial Origin: A Review. Int J Mol Sci. 2021 Sep 28;22(19):10468.
6. Vallabhajosyula S, Verghese D, Bell MR, Murphree DH, Cheungpasitporn W, Miller PE, et al. Fibrinolysis vs. primary percutaneous coronary intervention for ST-segment elevation myocardial infarction cardiogenic shock. ESC Heart Fail. 2021;8(3):2025–35.
7. Jurkovicová O, Cagán S. [Reperfusion arrhythmias]. Bratisl Lek Listy. 1998;99(3–4):162–71.
8. Wit AL, Janse MJ. Reperfusion Arrhythmias and Sudden Cardiac Death. Circ Res. 2001 Oct 26;89(9):741–3.
9. Kristanto H, Satrijo B, Widito S, Rizal A. Reperfusion Arrhythmia in Acute Myocardial Infarction: Clinical Implication and Management. Heart Sci J. 2022 Jan 1;3(1):4–14.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jonathan Edbert Afandy, Taslim

This work is licensed under a Creative Commons Attribution 4.0 International License.







